<sup>90</sup>Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors
Helena Lanzafame(Essen University Hospital), Rainer Hamacher(Essen University Hospital), Christoph E. Heilig(German Cancer Research Center), Pedro Fragoso Costa(Essen University Hospital), Sebastian Bauer(Science for Life Laboratory), Martin Schüler(German Cancer Research Center), Eva Wardelmann(University Hospital Münster), Simon Kreutzfeldt(German Cancer Research Center), Kim M. Pabst(West German Heart and Vascular Center Essen), Ilektra Antonia Mavroeidi(Essen University Hospital), Wolfgang P. Fendler(Essen University Hospital), Mélanie Desaulniers(Université de Sherbrooke), Sebastian Mühl(University of Münster), Jens T. Siveke(German Cancer Research Center), Michael Nader(Klinik und Poliklinik für Nuklearmedizin), Ina Pretzell(Essen University Hospital), Stephan Leyser(Düsseldorf University Hospital), Stefan Fröhling(German Cancer Research Center), Leila Kamkar(German Cancer Research Center), Ken Herrmann(Essen University Hospital)
Cited by 10
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k